153 related articles for article (PubMed ID: 38632130)
1. MALDI-mass spectrometry imaging as a new technique for detecting non-heme iron in peripheral tissues via caudal vein injection of deferoxamine.
Jin X; Shi X; Zhang T; Li X; Xie Y; Tian S; Han K
Anal Bioanal Chem; 2024 Jun; 416(14):3389-3399. PubMed ID: 38632130
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
[TBL] [Abstract][Full Text] [Related]
3. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
[TBL] [Abstract][Full Text] [Related]
4. Iron-chelating agents attenuate NMDA-Induced neuronal injury via reduction of oxidative stress in the rat retina.
Sakamoto K; Suzuki T; Takahashi K; Koguchi T; Hirayama T; Mori A; Nakahara T; Nagasawa H; Ishii K
Exp Eye Res; 2018 Jun; 171():30-36. PubMed ID: 29530811
[TBL] [Abstract][Full Text] [Related]
5. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
7. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
Liu Z; Lin TM; Purro M; Xiong MP
ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
[TBL] [Abstract][Full Text] [Related]
8. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
Liu Z; Qiao J; Nagy T; Xiong MP
J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
[TBL] [Abstract][Full Text] [Related]
9. Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy.
Xu L; Guan R; Yu B; Li Y; Liu H; Jiang Y
Int J Pharm; 2022 Sep; 625():122136. PubMed ID: 36029994
[TBL] [Abstract][Full Text] [Related]
10. Blocking action of parenteral desferrioxamine on iron absorption in rodents and men.
Levine DS; Huebers HA; Rubin CE; Finch CA
Gastroenterology; 1988 Nov; 95(5):1242-8. PubMed ID: 3169492
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
12. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice.
Tajima S; Ikeda Y; Sawada K; Yamano N; Horinouchi Y; Kihira Y; Ishizawa K; Izawa-Ishizawa Y; Kawazoe K; Tomita S; Minakuchi K; Tsuchiya K; Tamaki T
Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E77-86. PubMed ID: 21917632
[TBL] [Abstract][Full Text] [Related]
13. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
[TBL] [Abstract][Full Text] [Related]
14. Reactive Oxygen Species-Triggered Dissociation of a Polyrotaxane-Based Nanochelator for Enhanced Clearance of Systemic and Hepatic Iron.
Liu Z; Simchick GA; Qiao J; Ashcraft MM; Cui S; Nagy T; Zhao Q; Xiong MP
ACS Nano; 2021 Jan; 15(1):419-433. PubMed ID: 33378155
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional Polymeric Micelles for Combining Chelation and Detection of Iron in Living Cells.
Liu Z; Purro M; Qiao J; Xiong MP
Adv Healthc Mater; 2017 Sep; 6(17):. PubMed ID: 28661064
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
[TBL] [Abstract][Full Text] [Related]
17. Deferoxamine deconditioning increases neuronal vulnerability to hemoglobin.
Peng D; Chen CA; Ruhela D; Li Y; Regan RF
Exp Cell Res; 2020 May; 390(1):111926. PubMed ID: 32112801
[TBL] [Abstract][Full Text] [Related]
18. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
[TBL] [Abstract][Full Text] [Related]
19. Effects of iron chelating agent on Schistosoma mansoni infected murine model.
Abdelgelil NH; Abdellatif MZM; Abdel-Hafeez EH; Belal US; Mohamed RM; Abdel-Razik AH; Hassanin KMA; Abdel-Wahab A
Biomed Pharmacother; 2019 Jan; 109():28-38. PubMed ID: 30391706
[TBL] [Abstract][Full Text] [Related]
20. Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption.
Cui S; Liu Z; Nagy T; Agboluaje EO; Xiong MP
Mol Pharm; 2023 Feb; 20(2):1285-1295. PubMed ID: 36622899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
